Chemotherapy Protocol

HAIRY CELL LEUKEMIA

CLADRIBINE (IV-5 day)

Regimen

- HCL – Cladribine (IV-5 day)

Indication

- Hairy cell leukaemia (this is an unlicensed dose schedule)

Toxicity

<table>
<thead>
<tr>
<th>Drug</th>
<th>Adverse Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cladribine</td>
<td>Skin rash, fever, myelosuppression, neurotoxicity</td>
</tr>
</tbody>
</table>

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

Patients treated with cladribine carry a lifelong risk of transfusion associated graft versus host disease (TA-GVHD). Where blood products are required these patients must receive only irradiated blood products for life. Local blood transfusion departments must be notified as soon as the decision to treat is made and the patient must be issued with an alert card to carry with them at all times.

Monitoring

Drugs

- FBC, LFTs and U&Es prior to initiating treatment

Dose Modifications

The dose modifications listed are for haematological, liver and renal function and some drug specific toxicities only. Dose adjustments may be necessary for other toxicities as well.

In principle all dose reductions due to adverse drug reactions should not be re-escalated in subsequent cycles without consultant approval. It is also a general rule for chemotherapy that if a third dose reduction is necessary treatment should be stopped.

Please discuss all dose reductions / delays with the relevant consultant before prescribing, if appropriate. The approach may be different depending on the clinical circumstances.

Haematological

No pre-treatment dose reductions or delays should be made for anaemia, neutropenia or thrombocytopenia.
Hepatic Impairment

No information available

Renal Impairment

The potential risks and benefits of cladribine should therefore be carefully considered before treatment is commenced in any patient with renal impairment (CrCl less than or equal to 50ml/min) and it should only be used with caution and close monitoring. Alternatives such as rituximab or interferon may be considered until renal function normalises. Discuss with the relevant consultant.

Other

Dose reductions or interruptions in therapy are not necessary for those toxicities that are considered unlikely to be serious or life threatening. For example, alopecia, altered taste or nail changes.

Skin

Skin rash which can be severe occurs in up to 80% of those treated with cladribine. Early treatment with topical or systemic corticosteroids is usually necessary.

Regimen

5 day cycle for 1 cycle

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Days</th>
<th>Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cladribine (Leustat)</td>
<td>0.12mg/kg</td>
<td>1, 2, 3, 4, 5</td>
<td>Intravenous infusion in 500ml sodium chloride 0.9% over 120 minutes</td>
</tr>
</tbody>
</table>

Dose Information

- Cladribine will be dose banded according to the agreed national dose bands (1mg/ml)

Administration Information

Extravasation

- Cladribine – neutral

Other

- This is an unlicensed dose and administration schedule for hairy cell leukemia. The hairy cell leukemia schedule involves a 24 hour continuous infusion for seven consecutive days which is difficult to administer in practice and inconvenient for the patient. Subcutaneous rather than intravenous cladribine should be used in preference in most patients. The schedule described here is licensed for the treatment of chronic lymphocytic leukemia.
**Additional Therapy**

- No antiemetics are required with cladribine
- Allopurinol 300mg once a day oral for 7 days oral
- Anti-infective prophylaxis starting on day 6 and continued until the lymphocytes are above $1 \times 10^9/L$ (this may be years post treatment);
  - aciclovir 400mg twice a day oral
  - co-trimoxazole 960mg once a day on Monday, Wednesday and Friday only oral
- Mouthwashes according to local or national policy on the treatment of mucositis.
- Gastric protection with a proton pump inhibitor or a $H_2$ antagonist may be considered in patients considered at high risk of GI ulceration or bleed.

**Addition Information**

- The Leustat brand is the only brand that is licensed for intravenous administration

**Coding**

- Procurement –
- Delivery –

**References**

1. Robak T, Jamroziak K, Gora-Tybor J et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective randomised multicentre trial.
REGIMEN SUMMARY

Cladribine (IV)

Day 1

1. Warning – Check blood transfusion status
   Administration Instructions
   Patients treated with cladribine carry a lifelong risk of transfusion associated graft versus host disease. Where blood products are required these patients must receive ONLY IRRADIATED BLOOD PRODUCTS for life. Ensure transfusion departments are notified and the patient has been issued with an alert card

2. Cladribine 0.12mg/kg intravenous infusion in 500ml sodium chloride 0.9% over 120 minutes

   Day 2, 3, 4, 5

3. Cladribine 0.12mg/kg intravenous infusion in 500ml sodium chloride 0.9% over 120 minutes

   Take Home Medicines (day 1 only)

4. Aciclovir 400mg twice a day for 28 days oral
   Administration Instructions
   Start on day 6 of the cycle

5. Co-trimoxazole 960mg once a day on Monday, Wednesday and Friday for 28 days oral
   Administration Instructions
   Start on day 6 of the cycle

6. Allopurinol 300mg once a day for 7 days oral
This chemotherapy protocol has been developed as part of the chemotherapy electronic prescribing project. This was and remains a collaborative project that originated from the former CSCCN. These documents have been approved on behalf of the following Trusts:

- Hampshire Hospitals NHS Foundation Trust
- NHS Isle of Wight
- Portsmouth Hospitals NHS Trust
- Salisbury Hospital NHS Foundation Trust
- University Hospital Southampton NHS Foundation Trust
- Western Sussex Hospitals NHS Foundation Trust

All actions have been taken to ensure these protocols are correct. However, no responsibility can be taken for errors that occur as a result of following these guidelines.